Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Luminescence. 2009 Sep-Oct;24(5):324-31. doi: 10.1002/bio.1112.
In order to facilitate the discovery and investigation of anti-cancer therapeutics under physiological conditions, we have engineered the ovarian cancer cell line, HM-1/luc, in mice. This cell stably expresses firefly luciferase and produces light that can be detected using an in vivo imaging system (IVIS). Parental HM-1 cells cause severe carcinomatous peritonitis to B6C3F1 mice, but not to C57BL6 mice. Established HM-1/luc cells showed pathologically similar findings to HM-1 cells. HM-1/luc cells were injected into the peritoneal cavity of B6C3F1 mice and IVIS 2000 was conducted weekly after inoculation to monitor intra-peritoneal tumor growth. The mice were divided into three groups: non-CDDP-treated (control) and CDDP-treated (0.2 and 0.4 mg). A disease-suppressive effect of the CDDP was reflected by the significantly prolonged survival of the CDDP-treated mice (control 23 +/- 1.9 days, CDDP 0.2 mg 29.6 +/- 2.9 days; p < 0.05); the total photon and area of flux were decreased. The optical imaging of intraperitoneal tumors via in vivo bioluminescence is effective for noninvasive monitoring and semi-quantitative analysis. Our syngeneic mouse model has the relevant clinical features of ovarian cancer, which makes it a useful model for developing new ovarian cancer therapies.
为了在生理条件下促进抗癌疗法的发现和研究,我们在小鼠中构建了卵巢癌细胞系 HM-1/luc。该细胞稳定表达萤火虫荧光素酶,并产生可通过活体成像系统(IVIS)检测到的光。亲本 HM-1 细胞会导致 B6C3F1 小鼠发生严重的癌性腹膜炎,但不会导致 C57BL6 小鼠发生。已建立的 HM-1/luc 细胞表现出与 HM-1 细胞相似的病理发现。将 HM-1/luc 细胞注入 B6C3F1 小鼠的腹腔中,并在接种后每周进行 IVIS 2000 以监测腹腔内肿瘤生长。将小鼠分为三组:非顺铂治疗(对照)和顺铂治疗(0.2 和 0.4 mg)。顺铂的疾病抑制作用反映在顺铂治疗组小鼠的生存时间显著延长(对照组 23 +/- 1.9 天,顺铂 0.2 mg 29.6 +/- 2.9 天;p < 0.05);总光子和通量面积减少。通过体内生物发光进行的腹腔内肿瘤的光学成像可有效进行非侵入性监测和半定量分析。我们的同源小鼠模型具有卵巢癌的相关临床特征,使其成为开发新的卵巢癌治疗方法的有用模型。